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Combating Mutations In Genetic Disease And Drug 
Resistance: Understanding Molecular Mechanisms to 
Guide Drug Design 
Abstract 
Introduction: Mutations introduce diversity into genomes, leading to selective changes and 
driving evolution. These changes have contributed to the emergence of many of the current 
major health concerns of the 21st century, from the development of genetic diseases and 
cancers to the rise and spread of drug resistance. The experimental systematic testing of all 
mutations in a system of interest is impractical and not cost-effective, which has created 
interest in the development of computational tools to understand the molecular consequences 
of mutations to aid and guide rational experimentation. 
Areas covered: Here we discuss the recent development of computational methods to 
understand the effects of coding mutations to protein function and interactions, in particular in 
the context of the 3D structure of the protein. Using these methods, novel insights into the 
mechanistic effects of mutations in disease and drug resistance can be obtained, which can 
be used to guide treatment options and design better, more efficient and personalised 
therapeutics. 
Expert opinion: While significant progress has been made in terms of innovative tools to 
understand and quantify the different range of effects in which a mutation or a set of mutations 
can give rise to a phenotype, a great gap still exists when integrating these predictions and 
drawing causality conclusions linking variants. This often requires a detailed understanding of 
the system being perturbed. However, as part of the drug development process it can be used 
preemptively in a similar fashion to pharmacokinetics predictions, to guide development of 
therapeutics less prone to the development of resistance, and help guide the design and 
analysis of clinical trials, patient treatment and public health policy strategies. 
Keywords 
Mutational Analysis, Genetic Diseases, Drug Resistance, Cancer, Drug Design, Molecular 
Mechanism, Genotype-Phenotype Association. 
Article highlights 
● Scalable and reliable structural based computational approaches are providing 
detailed insight into the molecular consequences of coding mutations. 
● These have been used to guide patient treatment strategies for renal cell carcinoma 
and genetic diseases. 
● Using these methods, drug resistance mutations can be identified and predicted. 
● Used in a preemptive fashion, these can help guide drug development in the search 
for new therapeutics less likely to develop resistance. 
● Mutations can give rise to a phenotype through different molecular mechanisms which 
can be assessed via integration of computational methods.  
1. Introduction 
Changes at the genetic level can result in drastic changes in cellular phenotypes and 
behaviour. These changes can lead to disease, or provide selective advantages that promote 
the development of drug resistance. In particular, non-synonymous single nucleotide 
polymorphisms (nsSNPs) within the protein coding regions of the genome have been strongly 
associated with occurrence and predisposition of human disease and drug resistance, 
sparking great interest from the research community. 
 
The rapid developments in high-throughput sequencing, including dramatic drops in the cost, 
have created vast opportunities to understand the link between our genomes and phenotypes. 
This has opened up the promises of personalised medicines, targeted therapies and targeted 
public health policies. In order to fully realise the potential of these developments, however, 
we still need to improve our understanding of what are the molecular consequences of a given 
mutation, and how do these lead to a given phenotype. 
 
While considerable resources have been invested in the experimental evaluation of genomic 
mutations, characterizing mutation effects is a challenging task and impractical to 
systematically experimentally evaluate all possible mutations for a given protein of interest, 
even more considering the range of different mechanisms in which mutations can affect 
protein function and interactions. Traditional experimental approaches are also not efficient 
enough or don’t achieve scalability required to provide real time guidance into patient 
treatment and public health policy. This has led to significant interest in the development of 
computational approaches to rapidly and accurately evaluate the effects of mutations. Figure 
1 summarises how in silico mutation analysis can be helpful in deconvoluting genotype-
phenotype associations obtained from the wealth of genomic variation generated from 
sequencing efforts, including shedding light into disease predisposition and its mechanisms in 
a molecular level. Such methods can also be used to mutation prioritization for further 
experimental investigation, identification and anticipation of resistant variants and resistance 
hot-spots, knowledge that can be applied in the design of drugs less prone to resistance as 
well as to drive the development of public health policies and aid in establishing more 
appropriate and personalised treatments. 
 
2. Analysing the effects of mutations  
The two most commonly used methods by clinical geneticists to look at the effects of coding 
nsSNP mutations in the human genome are SIFT 1 and Polyphen 2. Other approaches include 
CADD3 and MutationTaster4. These approaches use the protein sequence to evaluate whether 
a given mutation is likely to be pathogenic or not. However, they have been limited by the lack 
of mechanistic information they provide and their over-estimation of mutations likely to be 
pathogenic 5. Structural approaches can complement these analyses by providing detailed 
mechanistic information, but historically have involved a trade-off between scalability and 
molecular level mechanistic information, with molecular dynamics approaches providing 
greater atomic detail, but proving impractical for comprehensive analysis of a large number of 
different mutations. 
 
In the 1990’s, efforts to utilise the expanding structural information available for many proteins 
led to the development of SDM 6 the first method for predicting the effects of mutations on 
protein folding and stability. Subsequent efforts by other groups led to a range of methods to 
predict the same effects, improving upon the accuracy but not considering the other potential 
structural effects mutations might lead to. 
 
This was first addressed through the systematic application of cut-off scanning matrices 7, 8 to 
quantitatively and scalably predict the effects of mutations on the binding affinities to other 
ligands, including other proteins, nucleic acids, small molecules and metal ions9-14. Table 1 
presents a summary of the main structure-based methods proposed over the past years to 
analyse the different effects of mutations on coding regions. While this started to allow the 
deconvolution of the individual molecular changes that might be occurring, the big question 
limiting their application, especially in a clinical setting, was how do these individual effects 
combine to lead to a phenotype? Recent efforts have started to integrate these structural 
effects in order to better understand phenotypes, and have been used to look at a number of 
different human health problems driven by mutations in protein coding regions 14-22. 
 
 
  
Table 1. Recent structure based computational methods for analysing the effects of 
coding mutations. 
Method Web server* Publication 
year 
Reference† 
Effects of Mutations on Protein Stability and Folding 
SDM http://www-cryst.bioc.cam.ac.uk/~sdm/sdm.php  
http://structure.bioc.cam.ac.uk/sdm2  
2011 
2017 
23 
24 
PoPMuSiC 2.1 http://babylone.ulb.ac.be/popmusic 2011 25 
mCSM-Stability http://structure.bioc.cam.ac.uk/mcsm/stability 2014 13 
DUET http://structure.bioc.cam.ac.uk/duet 2014 12 
ENCoM http://bcb.med.usherbrooke.ca/encom.php 2015 26 
MAESTROweb https://biwww.che.sbg.ac.at/maestro/web 2016 27 
STRUM http://zhanglab.ccmb.med.umich.edu/STRUM/ 2016 28 
ELASPIC http://elaspic.kimlab.org 2016 29 
Effects of Mutations on Protein-Protein Binding Affinity 
BeAtMuSiC http://babylone.ulb.ac.be/beatmusic/ 
 
2013 30 
mCSM-PPI http://structure.bioc.cam.ac.uk/mcsm/protein_prot
ein 
2014 13 
mCSM-AB http://structure.bioc.cam.ac.uk/mcsm_ab 2016 9 
MutaBind https://www.ncbi.nlm.nih.gov/projects/mutabind 2016 31 
Effects of Mutations on Protein-Nucleic Acid Interactions 
mCSM-NA http://structure.bioc.cam.ac.uk/mcsm/protein_dna  
http://structure.bioc.cam.ac.uk/mcsm_na 
2014 
2017 
13 
11 
Effect of Mutations on Protein-Small Molecule Interactions 
mCSM-Lig http://structure.bioc.cam.ac.uk/mcsm_lig 2016 14 
CSM-Lig http://structure.bioc.cam.ac.uk/csm_lig  2016 10 
* The URL links to the webserver to run the method. Links current as of April 2017. † The primary 
reference describing the method, and which should be cited if used. 
  
3. Using mutation analysis to guide treatment: towards 
personalised treatments 
3.1. Cancers 
By analysing the molecular effects of mutations in common renal cell carcinoma genes, 
including p15 and SDHA, these have been correlated to a patient’s risk of developing renal 
carcinoma. This was best demonstrated by recent studies looking at mutations in the von 
Hippel-Lindau protein (VHL) associated with the development of clear cell renal cell carcinoma 
(ccRCC) 15, 16, 32, 33. By assessing whether a mutation affected the stability of the protein, or 
disrupted interactions to Elongin or HIF-1α, a patient could be classified into high, medium 
and low risk groups that could help guide screening strategies and provide more focussed 
genetic counselling. The available clinical data from over 100 patients was integrated with a 
saturation mutagenesis analysis of all possible mutations on VHL producing Symphony, a 
relational database mapping experimental and predicted risks of mutations to its molecular 
mechanism, aiding the characterization of newly discovered variants. 
 
Understanding cancer genetics has been important for the diagnosis and treatment of a range 
of other cancers34, 35, with increasing interest in how the structural impacts of mutations can 
be used to interpret sequence information. This has led to recent efforts to map the COSMIC 
database onto protein structures. 
 
3.2. Mendelian Genetic diseases 
Alkaptonuria (AKU), also known as ochronosis or black bone disease, is a rare recessive 
inherited genetic disease and first metabolic disorder firstly described over 100 years ago. 
AKU is caused by coding mutations that disrupt structure and function of the enzyme 
homogentisate 1,2-dioxygenase (HGD), related to phenylalanine and tyrosine metabolism. 
HGD gene product folds to form a homo-hexamer disposed as two stacked trimers, quaternary 
structure which is necessary for enzyme function. 
 
Two comprehensive analysis on AKU causing mutations were carried out in an attempt to 
characterize the potential molecular mechanisms on which mutations could disruption enzyme 
activity 17, 18. 
 
Mutation effects on protein monomer stability as well as protein-protein and protein-ligand 
affinity were predicted with the DUET, mCSM-PPI and mCSM-Lig web servers respectively. 
Three mutation clusters emerged from this analysis, regarding the molecular mechanism for 
structure and function disruption: (a) mutations that greatly affected monomer stability, 
therefore preventing oligomer formation; (b) mutations greatly reducing protein-protein affinity 
between the hexamer components, also preventing proper oligomer formation and (c) 
mutations with mild effects on both monomer stability and protein-protein affinity, which 
together caused functional impairment. The structural analysis of mutations in other Mendelian 
diseases, for example Ornithine Transcarbamylase deficiency36, have identified that disease 
causing mutations lead to altered protein stability and interactions. Mutations with these 
molecular consequences occurred in roughly similar proportions to those observed in AKU.  
 These observations have been validated experimentally and expanded to examine all known 
disease causing mutations for inclusion in the HGD mutation database37, which could 
hopefully guide the development of new, more effective and personalised drugs to treat this 
condition. For example, subsequent efforts have identified molecular stabilizers that reverse 
the effects of the destabilising mutations, analogous to the recent successes on p53. They 
have also been used to classify patients in the SONIA2 clinical trial, as we know that the 
molecular mechanism of a mutation can alter how patients may respond to therapeutics38. 
 
Structural mutation analysis techniques have started to play important roles in the diagnosis 
of rare Mendelian genetic diseases. For example, establishing the genetic basis of epilepsy is 
a fundamental step for disease prognosis and choice of patient treatments38. Recently these 
methods were used to not only identify the genetic cause of a previously undiagnosed or 
characterized human cohesinopathy but also characterize the molecular mechanism, 
subsequently experimentally validated39. The potential for the structural characterisation of 
mutations to impact upon clinical practice will only continue to grow with the increasing 
availability of structural information, and routine use of exome sequencing in patient care. 
 
3.3. Screening for drug resistance in tuberculosis 
The reduction of sequencing costs, and improvements in accuracy and sensitivity, have led to 
interest in using high-throughput sequencing to diagnose patients, and identify drug resistance 
mutations. For infectious diseases such as tuberculosis (TB), where the drug susceptibility 
screening is time consuming and costly, genomic sequencing opens up the possibility of being 
able to more rapidly identify the correct treatment strategies for a patient, but also to guide 
public health policy by following the spread of resistance. Experimental innovations have 
allowed researchers to sequence the TB genome based on a sample of the patient’s sputum, 
and Public Health England is now sequencing all new TB cases in the UK.  
 
Many resistance mutations in TB have been well characterised, but one of the limitations of 
these approaches is how to interpret novel mutations identified within the genome. Due to the 
lack of horizontal gene transfer, TB is an ideal pathogen to apply structural based mutational 
analysis approaches. Looking at mutations in rpoB and katG, which leads to rifampicin and 
isoniazid resistance respectively, clear structural features were identified that correlated 
strongly with the resulting effectiveness of the drugs (MIC) 40. A number of resistance 
mutations have also been observed across protein-protein interfaces, which raises the 
interesting hypothesis that similar to Mendelian disease mutations, those at interfaces might 
be prone to lead to disease and resistance because they have a lower fitness cost associated 
to them than those in the active site that completely disrupt activity 36, 41, 42. 
 
While previous experimental and clinical knowledge about the effect of a given mutation in a 
given strain on drug susceptibility will always provide the gold standard for predicting and 
identifying drug resistance, structural based approaches complement this limited available 
information by providing the power to look at novel mutations. 
 
4. Targeting resistance mutations: towards resistance-resistant 
therapies. 
4.1. HIV protease 1 Inhibitors 
HIV protease catalyses the cleavage of the polypeptide precursors into mature enzymes and 
structural proteins, an essential step in the HIV-1 replication cycle. Inhibitors targeting the HIV 
protease have been in clinical use since 1995 and include darunavir, amprenavir, atazanavir, 
nelfinavir, indinavir, saquinavir and lopinavir 43, 44. 
 
Due to the HIV’s error prone replication, resistance mutations against these inhibitors have 
evolved rapidly and been widely observed clinically, limiting the effectiveness of these 
therapies. These include mutations in the active site (V32I, L33F, I54M and I84V) that through 
changes in hydrogen bonding and Van der Waals interactions between the inhibitors and the 
catalytic site amino acids, can reduce their binding affinities 45, 46.  
 
A better understanding of the effects of mutations on inhibitor binding and their molecular 
mechanism giving rise to resistance are crucial for designing novel drugs, more effectively and 
less prone failure. Computational structure-based methods have an important in tackling this 
challenge. The mCSM suite was successfully used to predict the effect of the aforementioned 
mutations upon the binding affinities. Molecular dynamics simulations have also been used to 
elucidate the effects of the protease inhibitor resistance mutations D30N, I50V, I54M, and 
V82A, providing interesting mechanistic information on how these mutations alter binding 
affinities, including changes in the binding conformation (I50V), conformational changes 
(I54M) and large enthalpic changes reducing binding affinity (V82A) 47. While genomic 
methods have proven unreliable for phenotypic characterisation of HIV 48, this potentially offers 
a means to better leverage this information and suggests ways to guide new designs that 
avoid these common hot-spots. 
 
The last HIV protease inhibitor approved, darunavir, was designed with this in mind and is 
capable of inhibiting the replication of both wild-type and multidrug-resistant strains of HIV-1. 
While earlier inhibitors interacted with the side-chains of Asp-28 and Asp-30, darunavir 
contained a bis-tetrahydrofuranylurethane functional group that made close, tight interactions 
with the main chain of these residues, making only minimal interactions with the side chains 
49. This made darunavir less sensitive to substitutions in either of these positions. Figure 2A 
depicts an alignment between darunavir and a non-peptidic inhibitor GRL-085 and the 
interactions made by the inhibitors (Figures 2B and 2C, respectively). 
 
Many resistant strains against darunavir, however, have emerged. These mutations often lead 
to a change in the conformation of the active site residues, reducing affinity for darunavir, but 
also leading to a significant fitness cost 50. In the effort to avoid these resistance mutations, 
current medicinal chemistry efforts have identified potent inhibitors that differ from the currently 
approved protease inhibitors by the number and proximity of contacts to the main chains of 
these catalytic amino acids 49. These compounds will be hopefully even more effective 
therapeutics that are significantly less prone to develop resistance. 
 
4.2. Influenza neuraminidase inhibitors 
Influenza neuraminidase inhibitors (NAIs) are the major specific anti-influenza drugs used 
clinically, despite the emergence of resistance 51. Currently, the NAIs oseltamivir, zanamivir, 
peramivir and laninamivir (currently approved only in Japan) have been approved to prevent 
and treat influenza A and B 51-54. Many governments have stockpiled resources of these drugs 
in the event of an Influenza outbreak. During the recent H1N1 and H7N9 Influenza outbreaks 
significant resources were focussed on identifying and monitoring potential resistance 
mutations, primarily through genetic screening, with sporadic oseltamivir-resistant 2009 H1N1 
virus infections identified. Thus, understanding the mechanisms of influenza NA drug 
resistance is crucial to develop drugs that can get around mutations and be more successful 
to fight the epidemics and pandemics 51. 
 
A strong correlation has been observed between mutations that affect the slow binding and 
dissociation of these NAIs, and the association with resistance 55. Resistance mutations that 
have been observed to residues E119 and I222 of Influenza A lead to high and slight 
resistance to oseltamivir and zanamivir respectively 56. Figures 3A and 3B highlight these 
resistance hot-spots on the solved complex of the neuraminidase with oseltamivir and the 
interactions established on the wild-type protein. Mutations on E119, include substitutions to 
Gly, Asp, Ala, Ile and Val, lead to the loss of a salt bridge to the inhibitors 57, with zanamivir 
showing less susceptibility due to the presence of the 4-guanidino group that maintains typical 
interactions 51. 
 
Mutations at I222 alter the hydrophobic drug binding pocket. While I222R leads to a reduction 
in oseltamivir, peramivir and zanamivir effectiveness 52, 58, 59, the I222L mutation, which is also 
found in Influenza B, has been reported to not lead to significant drug resistance 51. The other 
common mutation in N2 is R292K, which leads to resistance against oseltamivir and peramivir 
and a slight reduction of zanamivir and laninamivir effectiveness 52. 
 
Following treatment with oseltamivir, the N1 subtype specific substitution H274Y has also 
been observed, leading to resistance to this drug and also peramivir, but not to zanamivir and 
laninamivir 60, 61. The change in volume of the side chains upon this mutation causes the 
carbonyl group of E276 to be shifted into the binding site of the enzyme, disturbing the 
hydrophobic pocket that would accommodate the pentyloxy group of oseltamivir 61. 
 
Therefore in efforts to overcome some of these resistance problems, the guanidino group of 
zanamivir and the hydrophobic pentyloxy group of oseltamivir were merged 60. The guanidino 
group was capable of inhibiting the spread of Influenza A with the hydrogen bond interactions 
between the guanidino group and neuraminidase binding site crucial for the inhibition of the 
enzyme and virus replication 61, 62. However, the inhibition profile of MS-257 and zanamivir 
was comparable against the E119V and I222L mutant strains 51. 
 
The sequence database compiled by the WHO containing lists of amino acid substitutions in 
the neuraminidase has been widely used to identify key mutations and regions, guiding 
genomic analysis of resistance and proving invaluable for testing new compounds targeting 
inhibition of neuraminidase 63, 64. It has also facilitated the use of next-generation sequencing 
to detect resistance markers in the NA gene and predict the effect of drug treatment 65, which 
have been complemented by the use of structural based approaches to identify likely 
resistance mutations. 
 
4.3. Kinase drug development 
4.3.1 Kinase Inhibition 
Abnormal regulation of kinases through occurrence of mutations is responsible for many 
human diseases, including metabolic disorders and certain types of cancer 66. The 
development of small molecule kinase inhibitors has therefore been seen as an attractive 
treatment option 67. Unlike conventional chemotherapy (cytotoxic), molecular targeted 
therapies using kinase inhibitors are designed to act at specific biological points that are 
essential for development of tumour cells 68. 
 
The design of kinase inhibitors has great impact on their efficacy and sensitivity to resistance. 
The first kinase inhibitors developed targeted the ATP binding site via competitive binding. As 
resistance to these inhibitors was identified, other strategies including allosteric and covalently 
bound inhibitors were used to avoid these common resistance mutations 67. 
 
4.3.2 ATP-competitive inhibitors - First generation 
ATP-competitive kinase inhibitors inhibit ATP binding in the catalytic site of the target kinase, 
or bind at alternative sites to induce conformational molecular changes that inhibit the activity 
of the enzyme 68. Imatinib was the first kinase small molecule inhibitor clinically approved by 
the U.S. Food and Drug Administration (FDA) for treatment of chronic myeloid leukemia 69. 
Imatinib binds to the active site of the target enzyme preventing other substrates from 
phosphorylation and consequently inhibiting kinase activity. Figure 4A shows the Abelson 
tyrosine-protein kinase 2 (ABL2) in complex with imatinib. The inhibitor only binds to the 
enzyme when it is in inactive conformation. Another example of an inhibitor with a mechanism 
similar to imatinib is gefitinib which is used for treatment of non-small-cell lung cancer through 
inhibition of the epidermal growth factor receptor (EGFR).  
 
Despite the success of imatinib, studies have shown that patients can develop resistance and 
relapse after initial response to therapy. The effect of mutations linked to imatinib resistance 
were analysed by mCSM-Lig 14, which could correctly identify resistance mutations located 
even quite distal from the active site. mCSM-Lig quantitatively predicts the effect of mutations 
on small molecule affinity. Resistance mutations of competitive inhibitor, however, can exist 
by shifting the preference of the protein towards the natural ligand (ATP), not necessarily by 
dramatically reducing the affinity of the protein to the drug. Interestingly, using a fold-ratio 
between the predicted affinity effect on the natural ligand and the drug, mCSM-Lig was 
successful in identifying the majority of the imatinib resistance mutations. 
 
Several mechanisms of resistance have been observed, including mutations in the BCR-ABL 
kinase domain, with the most common resistant observed the gatekeeper mutant T315I 70. 
This amino acid substitution eliminates a critical oxygen molecule needed for hydrogen 
bonding between imatinib and the ABL kinase, and also introduces a steric clash preventing 
drug binding. The gatekeeper residue determines the relative accessibility of a hydrophobic 
pocket located adjacent to the ATP binding site, which is important for imatinib binding given 
that hydrophobic interactions are crucial for inhibitor binding affinity 67, 71, 72. In fact, mutations 
in gatekeeper residues have also been studied for other kinases in different types of cancer, 
such as the Threonine 790 of EGFR in Lung cancer that mutates to a methionine (T790M) 
increasing the affinity for ATP and making it difficult for the gefitinib to compete for the binding 
site 73-75. Such mechanisms of resistance have contributed to the development of more 
sophisticated generations of inhibitors with mechanisms to overcome resistances conferred 
by these gatekeeper mutations. 
 
4.3.3 ATP-competitive inhibitors - Second Generation 
The second generation of small molecule kinase inhibitors preferentially bind to regions 
outside the ATP binding site, for example to the inactive conformation, also known as DFG-
out, of the protein kinase. The transition from the active conformation to DFG-out conformation 
exposes additional hydrophobic pockets adjacent to the ATP site that can be used by the 
inhibitors to stabilize the kinase in its inactive conformation 76, preventing ATP binding. 
 
Dasatinib is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a 
more potent inhibitor than imatinib that binds only when the ABL enzyme is in its inactive 
conformation. Dasatinib is also effective against several imatinib-resistant ABL mutations that 
occur in regions that are in contact with imatinib or mutations involved in stabilization of 
specific inactive imatinib-bound conformation of the enzyme. However, the T315I gatekeeper 
mutation is also resistant to dasatinib due crucial hydrogen bond with the T315 side chain 77. 
Figure 4B shows ABL1 in complex with dasatinib. The main residues involved in the binding 
of the drug are highlighted, including T315. 
 
4.3.4 Allosteric inhibitors - Third Generation 
These inhibitors regulate the kinase activity in an allosteric manner, exhibiting a higher degree 
of selectivity due the exploitation of binding sites and regulatory mechanisms that are specific 
to a particular kinase 67. Figure 4C shows the allosteric inhibitor CI-1040 binding MEK1 
immediately adjacent to the ATP binding site. 
 
This class of inhibitors can bind either to the kinase domain (or close to the ATP binding site) 
or to sites outside the kinase domain. These range of options for inhibiting the catalytic activity 
of kinases represent clear advantages over the ATP-competitive inhibitors 78, 79. However, the 
lack of methods to identify such inactive conformations or binding modes in kinases to drive 
the development of this type of inhibitor still remains a challenge 80. Inhibitors that disrupt 
formation of the higher order oligomers, which play an important role in achieving high signal-
to-noise throughout the signal transduction process, have also proven to be effective kinase 
inhibitors that avoid the common ATP resistance mutations 81-83. 
 
ABL001, also known as Asciminib, is a potent and selective third generation kinase inhibitor 
with activity against chronic myeloid leukemia and Philadelphia chromosome-positive (Ph+) 
acute lymphoblastic leukemia. ABL001 binds to the myristoyl pocket of ABL1 kinase leading 
to a formation of an inactive kinase conformation84. Recent studies have shown that treatment 
with ABL001 combined with ATP-competitive inhibitors can help prevent resistance in chronic 
myeloid leukemia85, 86. 
 
4.3.5 Covalent inhibitors - Fourth Generation 
Recent studies 87, 88 described a fourth class of kinase inhibitors that are capable of forming 
covalent bonds to the kinase active site, most frequently by reacting with a nucleophilic 
cysteine residue. Unlike first and second generation inhibitors, the fourth generation blocks 
the binding of ATP irreversibly preventing the kinase from being activated. Figure 4D shows 
the fourth generation inhibitor Neratinib (HKI-272) in complex with EGFR kinase T790M 
mutant, making a covalent bond to Cysteine 797. 
 
4.3.6 Tackling kinase inhibitor resistance 
Much of the effort to target and avoid resistance against common kinase inhibitors has 
focussed on the development of inhibitors with different modes of action. This has in part been 
driven by the lack of selectivity of the early inhibitors that targeted the ATP binding site- which 
is highly conserved among many proteins. Structural methods such as mCSM-lig and 
molecular dynamics approaches have been able to correctly identify and predict likely 
resistance mutations, which could also potentially facilitate the design of new inhibitors 
avoiding these resistance hot-spots, similar to the efforts in anti-viral inhibitor design. However, 
more practically, as sequencing of cancers is becoming more routine, these methods offer the 
opportunity to help guide the selection of the most effective therapeutics- facilitating the 
widespread implementation of personalised medicine. 
 
The advent of fast and precise computational methods to predict effect of mutations can be 
leveraged to assist and guide the development of new drugs. Since resistance can emerge 
from different molecular mechanisms, current predictors can be integrated in novel drug 
resistance identification methods that can then be used in large-scale screening to identify 
better protein targets, identify and avoid potential resistance hot-spots as well as optimize 
ligand affinity and selectivity, driving the experimental design of better, more potent and 
efficacious drugs. 
 
5. Expert Opinions 
While significant progress has been made in terms of innovative tools to understand and 
quantify the different range of effects in which a mutation or a set of mutations can give rise to 
a phenotype, a great gap still exists when integrating these predictions and drawing causality 
conclusions linking variants, compounded by the need for detailed information regarding the 
system/protein. The availability of scalable, effective computational methods to assess 
mutation effects creates new opportunities of development of such integrated approaches and 
decipher complex genomic background patterns, shedding light into their role in the 
emergence of a given phenotype and molecular mechanisms of action. This capability can 
then be used to systematically study, for instance, how drug resistance emerges on specific 
drug targets, aiding the drug development process. Initial efforts on that matter have focussed 
on preparing predictors and databases for specific diseases and proteins, however greater 
effort needs to be invested in making these predictors user friendly, integrated and accessible 
to geneticists. This is particularly important considering that most structural information is a 
snapshot of a protein conformation, but how mutations affect the equilibrium between different 
states can play a very important role in disease and drug resistance 89. A complementary and 
important effort refers to the collection and curation of experimental data regarding mutation 
effects linked to phenotype in comprehensive databases. This information forms the evidence 
set necessary for the proposal of novel computational methods as well as the improvement of 
current approaches. Initiatives like the Platinum database 90, the first curated online database 
linking effects of mutations on protein-small molecule affinity for complexes with known 
structures, are fundamental. 
 
Despite this limitation, these methodologies have already provided invaluable insights into 
many diseases. Current genomic analyses are dependent upon pre-existing information; 
either extensive genomic or biochemical analyses. This limits the insight and information that 
can be drawn regarding novel mutations. As these structural methods become more widely 
used, they will complement traditional analyses methods to provide much greater power from 
genomic analysis. 
 
In the shorter term, the ability of these methods to predict likely resistance mutations before 
they arise offers enormous potential throughout the drug development process. Peter 
Coleman first suggested that the design of inhibitors that resemble transition state analogues 
should be more resilient to the development of resistance. Out of this Zanamivir was 
developed, the first successful structure guided drug development, but as we have seen over 
the intervening years resistance against Relenza has been widely reported, although it has 
been less prone to resistance than Oseltamivir.  
 
During the development of a recent class of Mycobacterium tuberculosis IMPDH inhibitors, 
structural guided mutational prediction was used to identify likely resistance mutations, defined 
in this case as point mutations that disrupted inhibitor binding, but did not affect NAD binding, 
protein solubility or formation of the active tetramer. One mutation in particular, Y487C, was 
highlighted, and subsequently confirmed to be one of the few mutations to arise during 
resistance screening 91. Subsequent drug development attempts avoided this resistance hot-
spot and were active against the Y487C mutant 92. This also enables the analysis of multiple 
mutations, some of which have been characterised to facilitate the development of resistance. 
In many cases, these seem to increase protein stability or natural ligand binding, which can 
be decreased due to the primary resistance mutation. 
 
While current medicinal chemistry efforts are currently normally retroactive - we observe which 
mutations arise in the lab or clinic and then design new generations of inhibitors to target or 
avoid them - the power of computational mutational analysis enables us to pre-emptively 
identify likely resistance hot-spots, and to take this information under consideration when 
optimising candidate molecules. In a similar fashion to how experimental structures93-97 and 
pharmacokinetic predictors are now widely used to guide medicinal chemistry efforts 98, 
playing a role in dramatically reducing failure rates of clinical trials due to these problems. The 
use of in silico mutational analysis in the development of new therapeutics will hopefully avoid 
likely resistance mutations. While the evolutionary forces and the constant selective battle 
makes the development of resistance somewhat inevitable, this will hopefully aid in the 
development of the next generation of therapeutics that are more resistant to the development 
of resistance. 
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Figures 
 
Figure 1. The use of in silico mutational analysis to tackle drug resistance and genetic diseases. Sequencing efforts 
generate a wealth of genomic variation. Computational mutation analysis can help deconvolute genotype-
phenotype associations aiding in understanding the molecular mechanism of diseases and disease predisposition 
as well as in mutation prioritization for experimental validation, identification of resistant variants and resistance 
hot-spots, which can then fed into drug design pipelines as well drive the development of public health policies and 
choice of more appropriate and personalised treatments.  
 
 
  
Figure 2. HIV-1 protease in complex with the non-peptidic inhibitor GRL-085 and darunavir (PDB: 5COO and 
4HLA, respectively). A shows the two aligned structures of HIV-1 protease in complex with GRL-085 (light gray) 
and darunavir (dark gray). B depicts the main interactions between the key residues of the binding site of HIV-1 
protease and darunavir. C shows the interactions between GRL-085 and the wild-type protease, calculated by 
Arpeggio 99. 
 
 
 
 
  
Figure 3. Neuraminidase subtype 2 of Influenza A in complex with Oseltamivir (PDB: 4GZP). A shows the main 
resistance hot-spot residues Glu119, Asp151 and Ile222 shown as sticks. The two negatively charged residues 
interact with Oseltamivir via ionic interactions shown as dashes, as calculated by Arpeggio 99. Arg292, another 
important binding residue is also shown. B shows the four aforementioned residues and the oseltamivir molecule 
in a surface perspective. 
 
 
  
Figure 4. Four generations of kinase inhibitors. A shows ABL2 in complex with first generation kinase inhibitor 
Imatinib (PDB: 3GVU). Imatinib binds to the active site of the enzyme preventing other substrates from 
phosphorylation only when the ABL2 is in inactive conformation. B shows ABL1 in complex with second generation 
inhibitor Dasatinib (PDB: 2GQG). Dasatinib is a multitargeted tyrosine kinase inhibitor more potent than Imatinib 
due to its capability of binding to the enzyme in inactive imatinib-bound conformation, also effective against several 
imatinib-resistant mutations, except for T315I gatekeeper mutation as a result of a crucial hydrogen bond with T315 
(underlined) for the stabilization of the complex. C shows MEK1 in complex with CI-1040 allosteric kinase inhibitor 
adjacent to the ATP binding site of the enzyme (PDB: 1S9J). The third generation of kinase inhibitors can bind 
either to the kinase domain or to other sites giving them clear advantage over ATP-competitive in first and second 
generation. D shows EGFR mutant T790M/L858R in complex with fourth generation kinase inhibitor Neratinib 
(PDB: 3W2Q). Unlike first and second generation inhibitors, this fourth generation inhibitor binds covalently to the 
kinase active site, blocking ATP binding. 
 
 
 
 
